ASCO guidance recommends Iressa
Executive Summary
American Society of Clinical Oncology recommends use of AstraZeneca's Iressa for treatment of non-small cell lung cancer in updated guidance published in 1Journal of Clinical Oncology. FDA approved Iressa (gefinitib) May 5 (2"The Pink Sheet" May 12, 2003, p. 7)...
You may also be interested in...
Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say
Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said
Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA
The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.